PLANO, Texas–(BUSINESS WIRE)–STATinMED Research, a leading health economics and outcomes research (HEOR) company, announces Dr. Ami Claxton’s appointment as a Vice President of HEOR. Dr. Claxton has taken over leadership of STATinMED’s Plano office as well as company-wide expansion of service offerings, with new emphasis on systematic reviews, meta-analysis and dossiers. Dr. Claxton has 23 years of HEOR and management experience, including positions within the consultancy sector as well as leading industry institutions such as Eli Lilly and Company, where she played a key role in the development of Prozac Weekly. Dr. Claxton has an extensive publication record and has leveraged her background in statistics and epidemiology for molecule development and support, including strategic planning, clinical trials, and Phase III/IV real-world studies and a wide range of reviews and dossiers. Her expertise also includes epidemiological and pharmacoeconomic insight into a variety of therapeutic areas as well as biotechnology, psychometrics, diagnostics and molecular biology.
Dr. Claxton joins recently-appointed President Doug Brenner, PhD, MBA in initiatives to augment the scope of STATinMED Research service offerings, including additional research formats and data visualization strategies. Dr. Brenner states, “Along with her impressive technical expertise, Dr. Claxton is, at heart, a storyteller—both literally, as a published narrative nonfiction author and award-winning onstage contributor to The Monti, and figuratively, as a research scientist with a keen understanding of how to convey technical information in a concise and compelling manner, tailored to specific stakeholders. Her background and outstanding qualifications uniquely position her to lead STATinMED’s current research expansion and its talented team to new levels of excellence.”
About STATinMED Research
Founded in 2007, STATinMED Research is a leading HEOR company using real-world data to generate evidence that provides the pharmaceutical and health care industries with insight for drug development and patient access. Through customized research methodologies and a diverse set of data sources, STATinMED’s team of professionals develop strategies that deliver better clinical outcomes, higher cost savings and greater value at every stage of the pharmaceutical product life cycle. The company collaborates with its clients to deliver demonstrable results that allow for greater confidence in marketability, cost effectiveness, product development and economic vitality. STATinMED is headquartered in Plano, Texas, with offices in Michigan and New York. For more information, visit www.STATinMED.com and follow them on LinkedIn and Twitter.